Our United Corporation
大医集团
elsewhere's corpus does not cover Our United Corporation as a subject. The only material that names it are two Dalton Venture portfolio pieces that mention it in passing as an investee, without describing what the company does. No dedicated article or entity information is available.
AI-generated — may contain errors, please verify.
Coverage
From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies
"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
"The Made-in-China" Breakthrough Moment: DaYi Group and Hanno Medical Featured in Xinhua News Agency Report | TongNews
On August 27, Xinhua News Agency published a special report titled *"More and More 'Made in China': China's Medical Equipment Achieves New Breakthroughs"*, comprehensively presenting the leapfrog development of China's medical equipment industry since the 14th Five-Year Plan period. In the report, **TAICHI Medical Systems** and **Hanano Medical**, two portfolio companies of **Dowstone Capital**, were specifically named, with their product innovation achievements drawing attention. This reflects not only the breakthrough capabilities of the enterprises themselves, but also the acceleration of China's medical equipment industry toward self-reliance and comprehensive —
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
